RxDoctor Payments Data

Kristyn Turner

Family · Cockeysville, MDNPI 1336875772

Payments from drug & device makers

$1,245in general payments, 2019–2025

Across 54 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$472
  • Exact Sciences$188
  • Lilly USA, LLC$165
  • Merck$97
  • AbbVie$72
  • Novo Nordisk$41
  • plus $209 from 9 others

What the payments were for

  • Food & beverage$1,245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,245 in reported general payments places this provider in the 75th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$37,680
Medicare patients
120
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$21,514
MounjaroTirzepatide13$20,997
JardianceEmpagliflozin20$17,905
JanuviaSitagliptin Phosphate19$15,386
EliquisApixaban24$11,695
MyrbetriqMirabegron12$5,168
LevocarnitineLevocarnitine (With Sugar)14$2,451
SynthroidLevothyroxine Sodium18$2,222
Atorvastatin Calcium149$1,995
Ezetimibe-SimvastatinEzetimibe/Simvastatin12$1,756
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide12$1,589
Rosuvastatin Calcium21$971
Amlodipine Besylate104$950
Metoprolol Succinate56$703
Pantoprazole Sodium49$660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$41$21,51417 claims
Lilly USA, LLCMounjaro$165$20,99713 claims
MerckJanuvia$97$15,38619 claims
PfizerEliquis$472$11,69524 claims
AbbVieSynthroid$72$2,22218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,843 family providers in Maryland.

Other family in Cockeysville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →